AbbVie reports revenue of $17.4 billion and net income of $4.22 billion

what happened

According to TradingView, citing the 10-Q filing, AbbVie booked $17.4 billion in revenue for the current period, up from $15.78 billion a year earlier. Net earnings attributable to AbbVie came in at $4.22 billion, versus $186 million, and diluted earnings per share reached $2.37.

Over nine months, worldwide revenue climbed 11% to $49.4 billion, driven mainly by the United States and demand for newer medicines. Skyrizi sales grew 25% and Rinvoq rose 23%, more than offsetting the decline of Humira amid biosimilar competition. The FDA also approved Juvmo for Parkinson's disease.

why it matters

For investors, the key point is that growth rests on newer drugs rather than only the legacy portfolio. The company also pledged a 10-year, $100 billion commitment to U.S. research, development and capital investment under a government access agreement, which could shape its long-term spending.

market impact

AbbVie shares: revenue and newer-drug growth support the stock

• ▲AbbVie shares pressure up — revenue rose 10.3% and newer medicines are growing faster than older ones

tags

instruments